Improving drug delivery for heart disease treatment
Targeted drug delivery for the treatment of cardiovascular disease and its clinical complications
This study is exploring a new way to deliver heart disease treatments directly to the areas that need them most, using tiny particles that can help the medicine work better for people with conditions like atherosclerosis and thrombosis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project ID | NIH-11010388 on NIH RePORTER |
What this research studies
This research focuses on enhancing the delivery of therapies specifically to areas affected by cardiovascular diseases, such as atherosclerosis and thrombosis. The approach involves using advanced nanoparticle technologies to create targeted drug delivery systems that can improve the accumulation of treatments at the sites of disease. By utilizing cell-mediated delivery methods, the researchers aim to ensure that these nanoparticles effectively reach and treat the problematic areas in the blood vessels. This innovative strategy could lead to more effective treatments for patients suffering from heart-related conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with atherosclerosis or venous thrombosis.
Not a fit: Patients with non-cardiovascular diseases or those without significant atherosclerotic or thrombotic conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cardiovascular diseases, potentially reducing the risk of heart attacks and strokes.
How similar studies have performed: Previous research has shown promise in using targeted drug delivery systems for other conditions, indicating potential success for this novel approach in cardiovascular disease.
Where this research is happening
Winston-Salem, United States
- Wake Forest University Health Sciences — Winston-Salem, United States (Active)
Researchers
- Principal investigator: Maiocchi, Sophie — Wake Forest University Health Sciences
- Study coordinator: Maiocchi, Sophie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.